Elliott Sigal, M.D., Ph.D.
Elliott Sigal, M.D., Ph.D., is a former executive vice president and director of Bristol-Myers Squibb (BMS). He served as chief scientific officer and president of R&D for BMS from 2004 until 2013. Under his leadership, 14 new medicines came to market including Erbitux (colon cancer), Baraclude (hepatitis B), Orencia (rheumatoid arthritis), Sprycel (leukemia), Eliquis (stroke) and Yervoy (melanoma). He built BMS research into a lead position in immuno-oncology, which is revolutionizing the practice of medicine in cancer. In 2012, Dr. Sigal was named the best R&D chief in the pharmaceutical industry by Scrip Intelligence. He currently serves as venture partner and senior advisor to the healthcare team of New Enterprise Associates and also consults for select biotechnology companies. He serves on the Board of Directors for Adaptimmune Therapeutics plc, Vir Biotechnology, Inc. and Alnylam Pharmaceuticals, Inc. He is co-chair of Amgen’s scientific advisory board and a member of the Scientific Steering Committee for the Parker Institute for Cancer Immunotherapy. Dr. Sigal joined BMS in 1997 and held roles in both discovery and development before ascending to chief scientific officer. Positions prior to BMS included a faculty appointment at University of California, San Francisco (UCSF), senior executive roles at Syntex/Roche and chief executive officer of the genomics firm, Mercator Genetics. Dr. Sigal received his medical degree from the University of Chicago in 1981 and trained in Internal Medicine and Pulmonary Medicine at UCSF. Prior to medical school he received a bachelor’s degree, medical degree and doctorate degree in industrial engineering from Purdue University.